Edition:
United States

Hologic Inc (HOLX.OQ)

HOLX.OQ on NASDAQ Stock Exchange Global Select Market

42.71USD
4:00pm EDT
Change (% chg)

$0.08 (+0.19%)
Prev Close
$42.63
Open
$42.62
Day's High
$42.92
Day's Low
$42.48
Volume
419,923
Avg. Vol
739,588
52-wk High
$42.97
52-wk Low
$32.64

Latest Key Developments (Source: Significant Developments)

Cynosure says Compensation Committee established $13 mln cash pool from making severance payments related to Hologic deal
Wednesday, 22 Feb 2017 05:04am EST 

Cynosure Inc : Cynosure - Compensation committee established $13 million cash pool from making severance payments for persons without employment agreements relating to Hologic deal Source: (http://bit.ly/2lL68PF) Further company coverage: [CYNO.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Cynosure agrees to termination fee of $57.7 mln for Hologic deal
Tuesday, 14 Feb 2017 05:00pm EST 

Cynosure Inc :Hologic - upon termination of deal under specified circumstances Cynosure has agreed to pay co termination fee of about $57.7 million.  Full Article

Hologic to acquire Cynosure for $1.65 bln
Tuesday, 14 Feb 2017 07:50am EST 

Hologic Inc : Hologic to acquire Cynosure, leader in medical aesthetics systems and technologies, in all-cash tender offer that combines two complementary businesses . Deal for enterprise value of $1.44 billion net of cash . Deal for $66.00 per share . Deal immediately accretive to non-GAAP earnings per share . Transaction has been approved unanimously by boards of directors of both companies . Hologic expects to realize annualized cost synergies of approximately $25 million by third year after close . Deal corresponds to an equity value of approximately $1.65 billion . Says Cynosure will merge with a subsidiary of Hologic and become a wholly-owned subsidiary of Hologic . Transaction is expected to be fully funded with cash on hand, including proceeds from recently completed blood screening divestiture . Says following completion of transaction, Cynosure shares will be delisted from Nasdaq . Hologic forecasts deal adding approximately $0.03 to $0.05 to company's non-GAAP EPS in balance of fiscal 2017 . Under terms of agreement, unit to start tender offer to purchase outstanding shares of Cynosure common stock for $66/share in cash . Estimates that deal will enable company to accelerate pro-forma revenue growth by roughly 150 basis points over next several years . Estimates that deal will enable company to increase non-GAAP earnings per share (EPS) at "solid" double-digit rate over next several years.  Full Article

Hologic reports Q1 GAAP EPS of $0.30
Wednesday, 1 Feb 2017 04:01pm EST 

Hologic Inc : Sees FY 2017 revenue $2.79 billion to $2.83 billion . Qtrly revenue of $734.4 million increased 5.6%, or 6.3% in constant currency terms . Hologic announces financial results for first quarter of fiscal 2017 . Q1 non-GAAP earnings per share $0.52 . Q1 GAAP earnings per share $0.30 . Q1 earnings per share view $0.51 -- Thomson Reuters I/B/E/S . Q1 revenue $734.4 million versus I/B/E/S view $724.2 million . Constant currency guidance assumes that foreign exchange rates are same in fiscal 2017 as in fiscal 2016 . Sees FY 2017 earnings per share $2.73 to $2.77 . FY2017 earnings per share view $2.15, revenue view $2.96 billion -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $1.90 to $1.94 . "We forecast that divestiture of Blood Screening Business will accelerate both our top- and bottom-line growth rates" . Sees Q2 revenue $675 million to $685 million .Sees Q2 earnings per share $1.85 to $1.86.  Full Article

Hologic Q1 non-gaap EPS $0.52
Wednesday, 1 Feb 2017 04:01pm EST 

Hologic Inc : Hologic announces financial results for first quarter of fiscal 2017 . Qtrly revenue of $734.4 million increased 5.6 pct, or 6.3 pct in constant currency terms . Q1 non-gaap earnings per share $0.52 . Q1 gaap earnings per share $0.30 . Q1 earnings per share view $0.51 -- Thomson Reuters I/B/E/S . Q1 revenue $734.4 million versus I/B/E/S view $724.2 million . Constant currency guidance assumes that foreign exchange rates are same in fiscal 2017 as in fiscal 2016 . Sees FY 2017 revenue $2.79 billion to $2.82 billion . Sees FY 2017 earnings per share $2.73 to $2.77 . FY2017 earnings per share view $2.15, revenue view $2.96 billion -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $1.90 to $1.94 . Hologic Inc- "we forecast that divestiture of blood screening business will accelerate both our top- and bottom-line growth rates" . Sees Q2 revenue $675 million to $685 million .Sees Q2 earnings per share $1.85 to $1.86.  Full Article

Bovie Medical provides J-Plasma update
Tuesday, 31 Jan 2017 04:05pm EST 

Bovie Medical Corp : Bovie Medical provides J-plasma® update . Bovie Medical Corp - Exploring new sales channel partnerships to further scale J-plasma® in gynecology specialty .Bovie Medical Corp - Pilot program with hologic that expires at end of February 2017 will not be extended.  Full Article

Hologic completes divestiture of blood screening business
Tuesday, 31 Jan 2017 04:01pm EST 

Hologic Inc :Hologic completes divestiture of blood screening business.  Full Article

Hologic says CEO Macmillan's FY 2016 total compensation $10.8 mln
Friday, 20 Jan 2017 04:16pm EST 

Hologic Inc :CEO Stephen Macmillan's FY 2016 total compensation $10.8 million versus $11.3 million in FY 2015 - sec filing.  Full Article

Hologic to divest blood screening business to partner Grifols for $1.85 bln
Wednesday, 14 Dec 2016 04:01pm EST 

Hologic Inc : Expects to update its financial guidance for fiscal 2017 after transaction closes . Transaction has been approved by boards of directors of both companies. . For fiscal 2017 co's share of blood screening business was forecast to contribute $240 million revenue, GAAP EPS of $0.19, and non-GAAP EPS of $0.34 .Hologic to divest blood screening business to partner Grifols for $1.85 billion.  Full Article

U.S. HHS awards $4.1 mln to Hologic to develop better Zika blood screening test
Tuesday, 9 Aug 2016 01:46pm EDT 

U.S. Department of Health and Human Services: Awards $4.1 million to Hologic Inc to develop better Zika blood screening test . Under the one-year agreement, Hologic will advance the development of its Procleix Zika virus assay . Contract with Hologic could be extended up to 18 months and $6.2 million to support the clinical study Further company coverage: [HOLX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

More From Around the Web

BRIEF-Cynosure says Compensation Committee established $13 mln cash pool from making severance payments related to Hologic deal

* Cynosure - Compensation committee established $13 million cash pool from making severance payments for persons without employment agreements relating to Hologic deal Source: (http://bit.ly/2lL68PF) Further company coverage: